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Summary 
Interleukin 10 (IL-10) was first described for its ability to inhibit interferon 3' (IFN-3') production. 
Herein, we studied the balance between IFN-3, and Ibl0 production by human peripheral blood 
mononuclear cells (PBMC) in response to Staphylococcus aureus Cowan (SAC) or lipopolysaccharide 
(LPS). Monocyte depletion reduced ILl0 production by 90% and resulted in an increased IFN-3` 
production.  Addition of anti-IL-10  antibody to PBMC cultures also strongly increased IFN-3` 
production.  In contrast,  among various cytokines, only IFN-3` strongly reduced IL-10 synthesis 
by SAC- or LPS-activated PBMC and monocytes. Thus, IFN-3' has proinflammatory effects through 
the combination of two mechanisms:  (a) induction of early tumor necrosis factor ot (TNF-c~) 
and IL-13 synthesis; and (b) inhibition of the ddayed production of IL-10, an inhibitor of TNF-ol 
and Ib13 synthesis. Taken together,  the present data indicate that IFN-3' and IL-10 antagonize 
each other's  production  and function. 
F  unctions of immune cells are finely coordinated to ensure 
an adequate response to an antigenic stimulus, and part 
of this coordination is mediated by secreted cytokines. Among 
those, IL-10 (for review see reference 1) was recently discov- 
ered, as a mouse Th2 cell product, by its ability to suppress 
IFN-3` production by Thl cells (2). Further reports indicated 
that IL-10 can also be produced by other cell types, such as 
normal and transformed B cells (3, 3a), activated T cell clones 
(4), and activated monocytes (5). In addition,  II,-10 inhibits 
antigen presentation (6) and cytokine synthesis by monocytes 
(5), but induces B  cell growth  and differentiation  (7). 
In the present report, we studied the balance between IFN-3` 
and Ibl0 in activated human normal PBMC and monocytes. 
We show that endogenous IL-10 downregulates the produc- 
tion of IFN-3`, and that  IFN-3,, in a reciprocal fashion, in- 
hibits  the monocyte-dependent  production  of IL-IO. 
Materials and Methods 
Isolation of  Human Total PBMC and Subpolmlations.  Total  PBMC 
were isolated from healthy donors by Ficoll-Hypaque centrifuga- 
tion and separated into purified subpopulations of monocytes and 
PBL. Monocytes were isolated by elutrial centrifugation  as previ- 
ously described (8). The preparation was >90%pure, as controlled 
by flow cytometry (FACScan|  Becton Dickinson & Co., Moun- 
tain View, CA) with FITC-conjugated  anti-CD14 antibody (Leu 
M3;  Becton  Dickinson  & Co.)  and by May Griinwald  Giemsa 
staining. The monocyte population was >90% HLA-DR and <1% 
CD25 +  . To obtain purified PBL, total PMBC at 106 cells/ml were 
incubated with anti-CD14 antibody (IOM2; Immunotech, Luminy, 
France) at 1 #g/ml for 45 rain at 4~  Cells were washed three 
times with RPMI 1640 and gently mixed for 45 min with ferrous 
beads (Dynabeads M450; Dynal,  Oslo,  Norway) (five beads per 
target cell) at 4~  The bead-cell complexes were eliminated with 
a magnetic  separator. The PBL population  was >98% pure and 
usually contained  84%  CD3 + (T cells) and 6-13%  CD19 § (B 
cells). No change in lymphocyte phenotype was observed after im- 
munodepletion. 
Cell Culture.  Cells  were cultured in complete RPM11640 (Gibco 
Laboratories, Grand Island, NY) supplemented with heat-inactivated 
10% FCS (Multiser; Cytosystems, Castle Hill, Australia), 2 mM 
glutamine, 100 U/ml penicillin, 100 gg/ml streptomycin, 50 gg/ml 
gentamycin, and 20 mM Hepes buffer. Cultures  were performed 
in 96-well flat-bottomed plates (Falcon Labware, Oxnard, CA) at 
a final volume of 250 #1 with 2.5  x  10  s cells/well for PBMC. For 
monocytes,  these  cultures  were  performed  with  an  equivalent 
number of monocytes as in PBMC, calculated from the percent 
of monocytes. For the PBL population,  the cell density was calcu- 
lated as the total cell number minus  the number of monocytes. 
Cells were stimulated  with Staphylococcus aureus Cowan strain  1 
(SAC) at a 1:200 dilution (Pansorbin; Calbiochem-Behring Corp., 
La Jolla,  CA) or LPS (from Escherichia coli, serotype 0111:B4, 1 
~g/ml; Sigma Chemical Co., St. Louis, MO), alone or in combi- 
nation with various cytokines. Reagents to be tested were added 
at the onset of the culture and supernatants were harvested after 
48 h unless otherwise  indicated. 
Reagents.  Purified human cytokines from the following sources 
were used at the following concentrations: rlL-l~8 (0.5 ng/ml), rlL-6 
(40 ng/ml), and rTNF-oL (10 ng/ml), from Genzyme (Boston, MA); 
rlFN-3, (0.01-100 ng/ml) and rib2 (100 U/ml), from Amgen Bio- 
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Volume 177  February 1993  523-527 logicals (Thousand Oaks, CA); TGF-~ (0.5 ng/ml), from On- 
comembrane Inc. (Seattle, WA); Ib7  (10 ng/ml), from  R&D 
Systems (Minneapolis, MN); rlL-4 (10 ng/ml), rib3 (10 ng/ml), 
and rGM-CSF (100 ng/ml), from Schering-Plough Research Insti- 
tute (Bloomfield,  NJ). Ascitic fluid containing a neutralizing anti- 
body against IFN-~/B27  (9) and control ascitic fluid were used 
at  the  dilution  1:5,000. Neutralizing  anti-ILl0 mAb  19F1 (1 
/~g/ml) was kindly provided by Dr. J. S. Abrams (DNAX,  Palo 
Alto, CA) (10). 
Determinations of Cytokine Levels.  The production of Ibl0 was 
measured  by Ibl0-specific  ELISA (sensitivity,  100 pg/ml) using two 
rat mAbs kindly provided by Dr. J. S. Abrams (DNAX) (10): 9D7 
for coating and biotinylated 12G8 for detection. IFN-y levels were 
measured by ELISA (sensitivity, 100 pg/ml) as previously  described 
(9). Ibl-B, TNF-cr  and II.-6 levels were detected with an enzyme 
amplified sensitivity immunoassay (sensitivity, 100 pg/ml) kindly 
provided by Medgenix Diagnostics (Brussels, Belgium). 
Detection of Single Cell Cytokine Production (Enzyme-linleed Im- 
munos~t[ELISPOT D.  The cytokine  ELISPOT assay,  adapted  from 
the method described by Czerkinsky et al. (11), was used to study 
cytokine synthesis by total PBMC, purified monocytes, and PBL 
at the single cell level. Wells were coated overnight at 4~  with 
100/~1 of mAb 9D7 (30/zg/ml) for ILl0 ELISPOT assay (10) and 
mAb BE8 (20/zg/ml) for Ib6 ELISPOT assay  (12). After washing 
and saturation with PBS/1% BSA, serial dilutions ranging from 
2.5  ￿  104 to 3  x  102 cells/well were distributed in duplicate in 
a volume of 50/zl. Cells were incubated with 50 #1LPS (1/zg/ml) 
in the absence or presence of IFN-'y (10 ng/ml) for 48 h at 37~ 
To detect spot-forming cells,  biotinylated antibodies (12G8 for Ibl0 
and BE4 for II.-6 ELISPOT,  respectively)  (10, 12) were then added 
for 2 h in 100 #1 of PBS/1% BSA. After incubation at room tem- 
perature and washing, plates were incubated for 2 h at room tem- 
perature with 100/zl of alkaline phosphatase-conjugated  streptavidin 
(Jackson Immunoresearch, West Grove, PA). After washing, 50/~1 
substrate solution (5-bromo-4-chloro-3-indolyl  phosphate; I mg/ml; 
Sigma Chemical Co.),  diluted in  2-amino-2-methyl-l-propanol 
buffer, in 3% agarose (Bethesda Research Laboratories, Gaithers- 
burg, MD) was added to each well. The number of blue spots was 
enumerated after 12 h of  incubation at room temperature. Frequen- 
cies were calculated  as the ratio of  the number of  spots per 1,000 cells. 
Results 
Endogenous ILIO Produced by Monocytes Inhibits IFN-7 Produc- 
tion.  The production of IL-10 by total PBMC, purified mono- 
cytes,  and PBL was measured using a specific ELISA after 
48 h of culture with or without SAC, a polyclonal activator 
of both lymphocytes and monocytes (13), or LPS,  an acti- 
vator of monocytes. As shown in Fig. 1 A, low levels of IL-10 
were produced by unstimulated cell populations (0.37  •  0.12 
ng/ml, mean +_ SEM of 10 different experiments).  This spon- 
taneous secretion was greatly enhanced by the addition of 
SAC  (3.99  •  0.42  ng/ml).  Depletion  of  CD14 +  cells 
(monocytes) by magnetic beads strongly decreased the SAC- 
induced I1-.10 production to 0.27  •  0.09 ng/ml. When seeded 
at a cell density corresponding to the number of monocytes 
present in PBMC, monocytes isolated by dutrial centrifuga- 
tion also produced Ibl0 after SAC activation, but levels were 
lower than those obtained with total PBMC (1.60  •  0.27 
ng/ml for monocytes). After LPS stimulation, the levels of 
I1:10 were 1.52 •  0.28 ng/ml for PBMC, 0.68  •  0.17 ng/ml 
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Figure I.  Role  of monocytes 
in the production of 11:10. (A) 
Production  of  Ibl0 by total  PBMC 
(2.5  x 10  s cells/well),  PBL, and 
monocytes  in response to SAC or 
LPS, was measured  by ELISA  in 
48-h  supernatants. PBL  were 
seeded at a cell  density  equivalent 
to the total  cell  number  minus  the 
number ofmonocytes.  Monocytes 
were seeded at  a  cell density 
equivalent to the number of mo- 
nocytes  present  in PBMC. Results 
are expressed in nanograms per 
milliliter as the mean _+ SEM of 
10 independent  experiments,  each 
in triplicate. The production of 
1I:10 (B) and I1:6 (C) was mea- 
sured at the single cell level by 
using the  cytokine ELISPOT 
assay. Cells  were activated  for 48 h 
with LPS (1 #g/ml). The results 
are expressed  as the mean •  SEM 
of the percent of  cytokine-produc- 
ing cells in three independent  ex- 
periments, each in duplicate. 
for purified monocytes, and 0.13  +  0.04 for PBL, results 
that are significantly  lower than obtained with SAC stimula- 
tion (n  =  10, p <0.01, by the Wilcoxon T  test). 
The production of cytokine at a single cell level was esti- 
mated by the calculation of the frequency of spot-forming 
cells using the ELISPOT assay. Since SAC particles cannot 
be used in the ELISPOT assay because  they bind the con- 
jugate, cells were activated with LPS (1/~g/ml). The frequency 
of IL-10-secreting cells was 0.32  •  0.03% for PBMC, 0.66 
+- 0.05% for monocytes, and 0.05  _+ 0.01% for PBL (mean 
+_  SEM of three independent experiments; Fig. 1 B). The 
frequency of IL-10-secreting cells was "~20-fold lower than 
that of Ib6-producing  cells  (II.-6 spots:  7.1  •  0.4%  for 
PBMC, 11.6  •  0.7% for monocytes, and 0.4  •  0.1% for 
PBL) (Fig.  1 C). 
Since ILl0 has been identified by its ability to inhibit the 
IFN-'y synthesis, we have examined whether endogenous II-.10 
might downregulate IFN-'y production by SAC-activated 
PBMC. As shown in Fig. 2 A, removal of monocytes from 
PBMC reduced by 16-fold the amount of secreted IIA0 and 
increased by 10-fold that of IFN-% and this effect persisted 
over a 10-d culture period. Furthermore, PBMC cultures car- 
ried out in the presence  of purified neutralizing anti-IL-10 
19F1 produced eightfold more IFN-'y levels (mean of three 
experiments), whereas a purified isotype control antibody failed 
to do so (Fig.  2 B). 
IFN-T Inhibits ILIO Production.  In as much as I1-'10 in- 
hibited the production of IFN-'y, we considered whether 
IFN-y was able, in a reciprocal fashion, to inhibit Ibl0 secre- 
tion. Thus, we tested the effect of various cytokines on I1.-10 
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Figure 2.  Endogenous  II:10 
produced by monocytes inhibits 
IFN-3, synthesis. (A) PBMC and 
PBL activated by SAC particles 
were tested for their capacity to 
produce IL,10 and IFN-'7. Levels 
of Ibl0 and IFN-7 were measured 
at day 10 by ELISA. The results 
are expressed in nanograms  per 
milliliter as the mean +_ SEM of 
three  independent experiments, 
each in triplicate. (B) PBMC were 
activated by SAC particles (1:200) 
in  the  absence  or  presence  of 
purified anti-IL,10  mAb (19F1) and 
a control antibody, both used at 
a concentration of 1/~g/ml. Levels 
of IFN-3, were measured at day 
10 by ELISA. The results are ex- 
pressed in nanograms per millilit~c 
as the mean _+ SEM of three in- 
dependent  experiments,  each in 
triplicate. 
production by SAC-stimulated PBMC. As shown in Fig. 3 
A, IFN 'y was the only cytokine among the 10 tested able 
to significantly inhibit Ibl0 synthesis. A 50% inhibition of 
II-10 production was induced with 0.45 _+ 0.28 ng/ml IFN-? 
(mean of three independent experiments), and a maximal in- 
hibition (80-90%) with ~5-10 ng/ml (Fig. 3 B). The in- 
hibitory effect of IFN-3, was completely reversed in the pres- 
ence of anti-IFN-~/antibody (data not shown). At the single 
cell level, 10 ng/ml IFN-? reduced by twofold the number 
of Ibl0 spots generated by LPS-activated PBMC and mono- 
cytes (Fig. 3 C). Kinetic studies indicated that the secretion 
of II.-10 could be detected 9 h after SAC induction, reaching 
its maximum after 36 h. The inhibitory effect of IFN-3' was 
observed over the entire culture period (Fig. 3 D). Finally, 
whereas  IFN-3' inhibited Ibl0 production by PBMC and 
purified monocytes, it increased the production of TNF-o~ and 
IL-1B, but only weakly affected the IIr  production (Table 1). 
Taken together, these data indicate that endogenous I1.-10 
has an inhibitory effect on endogenous IFN-3' synthesis and 
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Figure  3.  IFN-? inhibits Ibl0 production. (A) PBMC  (2.5  x  10  s 
cells/well) were activated by SAC particles in the absence or presence of 
purified recombinant cytokines, used at the following concentrations: rlbl~ 
(0.5 ng/ml), rlb2 (100 U/ml), rib3 (10 ng/ml), rlL-4 (10 ng/ml), rib6 
(40 ng/ml), rlL-7 (10 ng/ml), rTNF-o~ (10 ng/ml), TGF-3 (0.5 ng/ml), 
rGM-CSF (100 ng/ml), and IFN-? (5 ng/ml). After 48 h, production of 
I1=10 was determined in the culture supernatants by Ibl0 ELISA. Results 
are expressed in nanograms per milliliter as the mean +  SEM of culture 
triplicates of three independent experiments, performed under identical 
conditions. (B) PBMC were stimulated in the absence or presence of in- 
creasing concentrations of IFN-% Results are expressed in nanograms per 
milliliter as the mean _+ SD of culture triplicates of one experiment repre- 
sentative of three. (C) The inhibitory  effect of IFN-? on II:10 production 
was investigated at the single cell level  using II--10  ELISPOT assay. PBMC, 
monocytes, and PBL were activated by LPS (1 Izg/ml) for 48 h in the ab- 
sence or the presence of IFN-"/(10 ng/ml). Results (spot number for 1.25 
x  104 cells) are expressed as the mean _+  SEM of duplicate determina- 
tions of two independent experiments.  (D) Monocytes (10  s cells/well) 
purified by elutrial centrifugation from normal PBMC were stimulated 
with SAC particles in the absence or the presence of 5 ng/ml IFN-'),. Su- 
pernatants were collected at the indicated times and assayed for II:10 levels. 
Results are expressed in nanograms per milliliter as the mean _+  SD of 
culture triplicates. 
Table  1.  Selective Effects of IFN-  7  on Cytokine  Production 
IL-10  IL-6  IL-1B  TNF-oe 
IFN-3,  (n  =  6)*  (n  =  5)  (n  =  5)  (n  =  5) 
PBMC  -  4.02  _+  0.48  636  _+  230  9.12  _+  1.89  17.92  _+  3.82 
+  1.01  +  0.26  576  _+  182  21.86  _+  3.93  36.37  _+  3.51 
Monocytes*  -  1.87  _+  0.35  560  +_  172  4.47  +_  0.71  15.30  _+  3.36 
+  0.72  _+  0.13  935  +  250  12.30  _+  3.23  40.16  _+  2.36 
Total PBMC  (2.5  x  10  s cells/well)  and purified monocytes were incubated with SAC particles for 48 h in the absence or presence of IFN-? (5 
ng/ml). Levels  of IL-IO, IL-6, IL-I~, and TNF-c~  were determined by specific  ELISA. Results are expressed in nanograms per milliliter as the mean _+ SEM 
of culture triplicates. 
* Number of experiments,  each in triplicate. 
t Monocytes were seeded at a cell density equivalent  to the number of monocytes  present in PBMC. 
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Discussion 
IL-1O was initially described as cytokine synthesis inhibi- 
tory factor  (CSIF),  a product of mouse CD4 + Th2 cells 
with regulatory  effects on Thl cells (2). The results presented 
in this report demonstrate the role of monocytes, within SAC- 
or LPS-activated human PBMC, in the production of ILl0. 
Levels of secreted IL-10 were in the nanogram range, a quan- 
tity that is *100-fold lower than that of I1.-6 but similar to 
that of IL-13. The ELISPOT assay  indicated that only a small 
proportion of PBMC and monocytes produced IblO.  The 
frequency of IL-10-secreting cells was m20-fold lower than 
that of II~6-producing  cells. Removal of  monocytes from SAC- 
activated PBMC resulted in an *16-fold decrease of II.,10 
production and, conversely, in a 10-fold increase in IFN-y 
production. Furthermore, addition of anti-IL-10 antibody also 
resulted in an increase of IFN-'y production. These observa- 
tions are in line with the initial description of Thl cell inhi- 
bition by Th2 cell-derived CSIF, but they suggest a balance 
occurring between T cells and monocytes rather than between 
T cell subsets (14). Note, however, that purified monocytes 
produced less II.-10 than PBMC containing an equivalent 
number of monocytes. This suggests a possible positive cooper- 
ation between monocytes and lymphocytes for the produc- 
tion of II.-10. 
One of the most striking findings of the present study is 
the demonstration that exogenous IFN-'y inhibits the produc- 
tion of ILIO by SAC-activated PBMC and monocytes. The 
inhibition of IL-10 secretion  by monocytes appears to be specific 
of IFN-3,, as GM-CSF (15), TNF-c~  (16), and II..1 (17), known 
stimulators of monokine production, or Ib4, a known in- 
hibitor of monokine secretion (18), had no significant effect 
on Ibl0 production. The IFN-3,-dependent inhibition of IL-10 
production was obtained both at the culture supernatant level 
and at the single cell level. Furthermore, the downregulation 
of Ibl0 synthesis by IFN-3~ did not result from a nonspecific 
inhibition of protein synthesis, as it increased SAC-induced 
Ibl/$ and TNF-ot production by PBMC and purified mono- 
cytes while downregulating I1.-10 production. Thus, IFN-3' 
acts as a monocyte-activating factor (for review see reference 
19), not only by enhancing:  (a) the release of oxygen rad- 
icals, (b)  their  tumoricidal activity,  (c)  their secretion  of 
proinflammatory cytokines such as TNF-ot,  Ibl,  and IL-6 
(20), and (d) their MHC class II antigen expression and their 
antigen-presenting activity, but also by blocking the produc- 
tion of II.-10, which decreases all the functions of monocytes 
described above (5, 6, 21). The IFN-q,-dependent downregu- 
lation of I1.,10 production by monocytes demonstrated here 
would support the speculation that the stimulatory effect of 
IFN-y on these cells may be a consequence of a decreased 
production of endogenous ILl0. However, the stimulatory 
effect of IFN-y on the early TNF-oe and IL-1B synthesis does 
not appear to be linked to the inhibition of ILl0 production, 
which occurs in the later stages of the culture. Thus, IFN-y 
activates monocytes/macrophages in a direct as well as an in- 
direct fashion by inhibiting the production of ILl0, which 
acts as a monocyte-deactivating  factor (21). 
An altered  balance  in the production of  either IblO or IFN-v 
will result in altered monocyte  activation, including the secre- 
tion of monokines and the presentation of antigen and thus 
lymphocyte activation. For example, at the onset of autoim- 
mune diseases, the role of IFN-3~ has been suggested for the 
increased MHC  class II  expression  and  proinflammatory 
cytokine production (22). In this situation,  the inhibitory 
effect of IFN-3, on IL-IO production would reduce the an- 
tiinflammatory properties of IIA0, leading to disease  perpetu- 
ation.  In conclusion,  the present  study demonstrated that 
IFN-3,  and  I1:10 antagonize  each other's production and 
function. 
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